Nuvalent, Inc. NUVL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Direct Expenses Related To Program by Product | ||||||
| Discovery Programs | $2.8M+31.4% | $3.03M+19.3% | $3.29M+57.9% | $3.42M+39.4% | $2.13M+1.6% | |
| Neladalkib | $26.32M-6.0% | $19.09M-17.3% | $30.05M+44.7% | $28.3M+99.3% | $28.01M+188% | |
| NVL-330 | $6.83M+72.3% | $5.76M+89.3% | $6.17M+301% | $5.93M+241% | $3.96M+101% | |
| Zidesamtinib | $12.31M-20.8% | $10.02M-46.4% | $16.67M-8.1% | $17.28M+16.1% | $15.55M+50.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Nuvalent, Inc. break its business down?
- Nuvalent, Inc. (NUVL) reports direct expenses related to program by product across 4 parts — Discovery Programs, Neladalkib, NVL-330 and Zidesamtinib. Each is extracted from the segment footnotes and tracked over time.
- Where does Nuvalent, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Nuvalent, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.